



EXPRESS SCRIPTS®

**Express Scripts Holding Company
Pharmacy and Therapeutics Committee
Proceedings
May 12, 2016**

New Drug Evaluations

The Committee reviewed the following new drugs.

- A. **Cabometyx**™ (cabozantinib tablets) Exelixis Inc.
- B. **Cinqair**® (reslizumab injection for intravenous use) Teva Respiratory
- C. **Inflectra**™ (infliximab-dyyb injection for intravenous use) Hospira/Pfizer
- D. **Kovaltry**® (antihemophilic factor [recombinant] for intravenous injection) Bayer
- E. **Nuplazid**™ (pimavanserin tablets) Acadia
- F. **Taltz**® (ixekizumab for subcutaneous injection) Eli Lilly
- G. **Venclexta**™ (venetoclax tablets) AbbVie/Genentech

New Indications for Existing Products

The Committee reviewed the following new indications for existing products: See product inserts for specific wording.

- A. **Gilotrif**® (afatinib tablets) Boehringer Ingelheim – New indication for the treatment of patients with metastatic squamous non-small cell lung cancer progressing after platinum-based chemotherapy.
- B. **Imbruvica**® (ibrutinib capsules) Janssen/Pharmacyclics – Expanded indication for the treatment of patients with SLL, as well as for patients with 17p deletion SLL.
- C. **ProAir RespiClick**® (albuterol sulfate inhalation powder) Teva – Expanded age indication for the treatment or prevention of bronchospasm in patients ≥ 4 years of age with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients ≥ 4 years of age. Previously, ProAir RespiClick was approved for use in patients ≥ 12 years of age.
- D. **Truvada**® (emtricitabine/tenofovir disoproxil fumarate tablets) Gilead – Change in weight limit to include pediatric patients weighing ≥ 17 kg. Truvada is now indicated for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients weighing at least 17 kg. Previously, Truvada was approved for use in pediatric patients ≥ 12 years of age and weighing ≥ 35 kg.
- E. **Viekira Pak**® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) AbbVie – Revised indication for use without ribavirin in patients with chronic hepatitis C virus (HCV) genotype 1b infection with compensated cirrhosis (Child-Pugh A). The new indication is as follows: for the treatment of adult patients with chronic HCV genotype 1b without cirrhosis or with compensated cirrhosis and genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. Previously, Viekira Pak was indicated for use with or without ribavirin for the treatment of patients with genotype 1 chronic HCV infection including those with compensated cirrhosis.
- F. **Xalkori**® (crizotinib capsules) Pfizer – New indication for the treatment of patients with metastatic non-small cell lung cancer whose tumors are ROS1-positive.



Public Information

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions.

- A. **BromSite**[™] (bromfenac ophthalmic solution) Sun Pharma
- B. **Descovy**[®] (emtricitabine/tenofovir alafenamide tablets) Gilead
- C. **Evomela**[™] (melphalan injection) Spectrum
- D. **Fycompa**[®] (perampanel oral suspension) CIII Eisai
- E. **Orfadin**[®] (nitisinone oral suspension) Swedish Orphan Biovitrum
- F. **Xtampza**[™] **ER** (oxycodone extended-release capsules [with DETERx[®]]) CII Collegium

All trademarks are the property of their respective owners.